Exercise of Options and Total Voting Rights

RNS Number : 7897T

Destiny Pharma PLC

29 March 2021

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Exercise of Options and Total Voting Rights

Brighton, United Kingdom - 29 March 2021 -   Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has issued and allotted 25,000 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") following an exercise of share options by a former employee.

Application will be made to the London Stock Exchange for the 25,000 new Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 2 June 2021 ("Admission").

Following Admission, the Company will have a total of 59,861,921 Ordinary Shares in issue. Shareholders may use this figure of 59,861,921 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[e-mail]  

[phone] 

Optimum Strategic Communications 

Mary Clark, Shabnam Bashir, Manel Mateus

[e-mail]  

[phone]

finnCap Ltd  (Nominated Advisor Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners  (Joint Broker) 

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

 About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  https://www.destinypharma.com

 

END

 

 

IOEUKRKRAVUOURR